JCR Pharmaceuticals
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 11/5/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (11)
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
Started: 2/14/2022
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
Started: 2/22/2023
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Started: 9/1/2019
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
Started: 7/26/2018
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Started: 1/1/2019
A Study of JR-141 in Patients With Mucopolysaccharidosis II
Started: 8/1/2018
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Started: 11/5/2024
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)
Started: 10/28/2021
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
Started: 10/4/2023
A Study of JR-171 in Patients With Mucopolysaccharidosis I
Started: 9/1/2020
A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Started: 3/30/2017